{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T21:52:07Z","timestamp":1755035527910,"version":"3.41.2"},"reference-count":4,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2022.1109950","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T12:39:49Z","timestamp":1676896789000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Editorial: Biology and treatment of high-risk CLL"],"prefix":"10.3389","volume":"12","author":[{"given":"Eugen","family":"Tausch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitka","family":"Malcikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Riches","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Edelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.481","article-title":"Understanding and managing ultra high-risk chronic lymphocytic leukemia","volume":"1","author":"Stilgenbauer","year":"2010","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1182\/blood-2018-01-826008","article-title":"High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies","volume":"132","author":"Dreger","year":"2018","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.187583","article-title":"TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics","volume":"103","author":"Campo","year":"2018","journal-title":"Haematologica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1109950\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T12:39:51Z","timestamp":1676896791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1109950\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":4,"alternative-id":["10.3389\/fonc.2022.1109950"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1109950","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"article-number":"1109950"}}